S100B Gene

S100B — S100 Calcium Binding Protein B

Pathway Diagram

```mermaid
flowchart TD
S100B["S100B<br/>Calcium-binding protein"]

S100B -->|"activates"| Neuroinflammation["Neuroinflammation<br/>Glial activation"]
S100B -->|"biomarker_for"| TBI["Traumatic Brain Injury<br/>Acute neural damage"]
S100B -->|"activates"| ALS["ALS<br/>Motor neuron disease"]
S100B -->|"activates"| MS["Multiple Sclerosis<br/>Demyelinating disease"]

S100B -->|"activates"| C1Q["C1Q<br/>Complement activation"]
S100B -->|"activates"| HMGB1["HMGB1<br/>Damage-associated<br/>molecular pattern"]
S100B -->|"activates"| TGM2["TGM2<br/>Transglutaminase 2"]

Neuroinflammation -->|"leads_to"| Microglial_activation["Microglial Activation<br/>Pro-inflammatory state"]
C1Q -->|"triggers"| Complement_cascade["Complement Cascade<br/>Synaptic pruning"]
HMGB1 -->|"promotes"| Cytokine_release["Cytokine Release<br/>IL-1beta, TNF-alpha"]

S100B -->|"biomarker_for"| BDNF["BDNF<br/>Neuroprotective factor"]
S100B -->|"associated_with"| Aging["Aging<br/>Cellular senescence"]

Microglial_activation -->|"causes"| Synaptic_loss["Synaptic Loss<br/>Neuronal dysfunction"]
Complement_cascade -->|"results_in"| Synaptic_loss
Cytokine_release -->|"contributes_to"| Neurodegeneration["Neurodegeneration<br/>Progressive cell death"]

Aging -->|"accelerates"| Neuroinflammation
Synaptic_loss -->|"leads_to"| Neurodegeneration

style S100B fill:#006494
style BDNF fill:#1b5e20
style Neuroinflammation fill:#ef5350
style TBI fill:#e

S100B — S100 Calcium Binding Protein B

Pathway Diagram

Overview

S100B Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

S100B is a gene encoding a calcium-binding protein of the S100 family, playing crucial roles in neuronal function, astrocyte biology, and neuroinflammation. Originally discovered as a brain-specific protein, S100B has emerged as a critical player in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This page provides comprehensive information about S100B's structure, function, signaling pathways, and therapeutic implications in neurodegeneration.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">S100 Calcium Binding Protein B</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>S100B</td></tr>
<tr><td><strong>Full Name</strong></td><td>S100 Calcium Binding Protein B</td></tr>
<tr><td><strong>Chromosome</strong></td><td>21q22.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[6275](https://www.ncbi.nlm.nih.gov/gene/6275)</td></tr>
<tr><td><strong>OMIM</strong></td><td>176990</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000122574</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P16401](https://www.uniprot.org/uniprot/P16401)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>92 amino acids</td></tr>
<tr><td><strong>Protein Family</strong></td><td>S100 EF-hand calcium binding proteins</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Brain Injury, Down Syndrome</td></tr>
</table>
</div>

Gene Structure and Evolution

The S100B gene is located on chromosome 21q22.3 and consists of three exons spanning approximately 4.5 kb of genomic DNA. The gene encodes a 92-amino acid protein with a molecular weight of approximately 10.5 kDa. S100B belongs to the S100 family of EF-hand calcium-binding proteins, which evolved through gene duplication events dating back over 500 million years [@marenholz2004].

S100 Protein Family

The S100 family comprises over 20 members in humans, characterized by:

• Two EF-hand calcium-binding motifs
• Homozygous or heterodimeric assembly
• Cell-type specific expression patterns
• Diverse functions in calcium signaling

Protein Structure and Biochemistry

S100B adopts a characteristic S100 protein fold consisting of:

• N-terminal EF-hand (site I): Low-affinity calcium-binding site (Kd ~10-50 μM)
• C-terminal EF-hand (site II): High-affinity calcium-binding site (Kd ~0.1-1 μM)
• Hydrophobic hinge region: Mediates protein-protein interactions
• C-terminal tail: Contains the Target-binding interface

Dimerization and Oligomerization

S100B functions primarily as a homodimer (S100B2), though higher-order oligomers (tetramers, hexamers) have been reported. Dimerization is essential for:

• Target protein recognition
• Enhanced calcium binding affinity
• Regulatory function

Normal Physiological Functions

Neurotrophic Activity

At nanomolar concentrations, S100B exhibits potent neurotrophic effects:

• Neurite extension: Promotes axonal and dendritic growth during development
• Synaptogenesis: Facilitates synapse formation and maturation
• Neuronal survival: Activates pro-survival signaling through various pathways

Calcium Homeostasis

S100B participates in intracellular calcium signaling by:

• Modulating calcium influx through voltage-gated calcium channels
• Regulating calcium release from intracellular stores
• Buffering cytosolic calcium concentrations

Astrocyte Function

As the most abundant astrocyte-specific protein, S100B serves multiple functions:

• Glial fibrillary acidic protein (GFAP) regulation: Modulates astrocyte intermediate filament expression
• Water homeostasis: Regulates aquaporin-4 expression and function
• Neuronal support: Provides metabolic and structural support to [neurons](/entities/neurons)

Extracellular Signaling

S100B can be secreted via a non-classical pathway and acts extracellularly:

• Receptor for Advanced Glycation Endproducts (RAGE): Primary extracellular receptor
• Toll-like receptors (TLRs): [TLR4](/entities/tlr4)-mediated signaling
• Neurotrophic effects: At low concentrations (nanomolar)
• Pro-inflammatory effects: At high concentrations (micromolar)

Signaling Pathways

RAGE-Mediated Signaling

S100B binding to RAGE activates multiple signaling cascades:

S100B → RAGE → NF-κB → Pro-inflammatory gene expression
↓
→ MAPKs (ERK1/2, p38, JNK) → Cell proliferation/differentiation
↓
→ PI3K/AKT → Pro-survival signaling
↓
→ NADPH oxidase → ROS production

p53 Pathway

S100B interacts with p53 tumor suppressor protein:

• Inhibits p53 tetramerization
• Blocks p53 DNA-binding activity
• Reduces p53-mediated [apoptosis](/entities/apoptosis)
• Modulates cell cycle progression

NF-κB Signaling

S100B activates NF-κB through multiple mechanisms:

• RAGE-dependent activation
• Direct interaction with IKK complex
• Promotion of IκB degradation

Disease Associations

Alzheimer's Disease (AD)

S100B is heavily implicated in Alzheimer's disease pathogenesis:

| Finding | Significance |
|---------|--------------|
| Elevated in AD brain | 10-50-fold increase in [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex) |
| Colocalizes with amyloid plaques | S100B+ [astrocytes](/entities/astrocytes) surround plaques |
| Elevated in CSF | Biomarker potential |
| Associated with [tau](/proteins/tau) pathology | Correlates with neurofibrillary tangles |

Mechanisms in AD

Parkinson's Disease (PD)

S100B alterations in PD include:

• Increased S100B expression in substantia nigra
• Association with dopaminergic neuron loss
• Glial activation in PD pathology
• Potential biomarker for disease progression

Amyotrophic Lateral Sclerosis (ALS)

In ALS:

• Upregulated in motor cortex and spinal cord
• Secreted by activated astrocytes
• Contributes to non-cell autonomous motor neuron toxicity
• May amplify excitotoxicity

Traumatic Brain Injury (TBI)

S100B serves as a clinical biomarker:

• Rapid elevation in serum after TBI
• Correlates with injury severity
• Predicts outcome
• Used in sports concussion assessment

Down Syndrome

Given the chromosome 21 location:

• Triplication leads to S100B overexpression
• Contributes to early-onset AD pathology
• Developmental abnormalities
• Accelerates neurodegeneration

Therapeutic Implications

Biomarker Potential

S100B has been investigated as a biomarker for:

• Traumatic brain injury severity
• Neurodegenerative disease progression
• Treatment response monitoring
• Astrocyte dysfunction

Therapeutic Targeting

Strategies targeting S100B include:

• Antisense oligonucleotides: Reduce S100B expression
• Small molecule inhibitors: Block S100B-RAGE interaction
• Neutralizing antibodies: Sequester extracellular S100B
• Natural compounds: Flavonoids that modulate S100B function

Key Publications

[@marenholz2004]: Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun. 2004;322(4):1111-1122. PMID: 15336978(https://pubmed.ncbi.nlm.nih.gov/15336978/)

[@donato2009]: Donato R, Sorci G, Riuzzi F, et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):1008-1022. PMID: 19110091(https://pubmed.ncbi.nlm.nih.gov/19110091/)

[@leclerc2009]: Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta. 2009;1793(6):993-1007. PMID: 19110054(https://pubmed.ncbi.nlm.nih.gov/19110054/)

[@rothermundt2003]: Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech. 2003;60(6):614-632. PMID: 12645008(https://pubmed.ncbi.nlm.nih.gov/12645008/)

[@van2003]: Van Eldik LJ, Wainwright MS. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci. 2003;21(3-4):97-108. PMID: 14530572(https://pubmed.ncbi.nlm.nih.gov/14530572/)

[@peskind2001]: Peskind ER, Griffin WS, Akama KT, et al. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int. 2001;39(5-6):409-413. PMID: 11578776(https://pubmed.ncbi.nlm.nih.gov/11578776/)

[@liu2022]: Liu J, Li S, Chen W, et al. S100B as an indicator of astrocyte activation and tau pathology in Alzheimer's disease. J Alzheimers Dis. 2022;85(4):1601-1613. PMID: 34882546(https://pubmed.ncbi.nlm.nih.gov/34882546/)

See Also

• [S100B Protein](/proteins/s100b-protein)
• [Astrocytes in Neurodegeneration](/cell-types/astrocytes)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [RAGE Signaling in Neurodegeneration](/mechanisms/rage-signaling)
• [NF-κB Pathway](/mechanisms/nf-kb-pathway)
• [Calcium Dysregulation in Neurodegeneration](/mechanisms/calcium-dysregulation)

External Links

• [NCBI Gene: S100B](https://www.ncbi.nlm.nih.gov/gene/6275)
• [UniProt: P16401](https://www.uniprot.org/uniprot/P16401)
• [Ensembl: ENSG00000122574](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122574)
• [OMIM: 176990](https://www.omim.org/entry/176990)

Overview

S100B Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of S100B Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving S100B Gene discovered through SciDEX knowledge graph analysis: